Tenofovir hydrate

Catalog No.S4879 Synonyms: GS-1278 hydrate

For research use only.

Tenofovir (GS-1278) hydrate blocks reverse transcriptase and hepatitis B virus infections.

Tenofovir hydrate Chemical Structure

CAS No. 206184-49-8

Selleck's Tenofovir hydrate has been cited by 2 Publications

Purity & Quality Control

Choose Selective Reverse Transcriptase Inhibitors

Other Reverse Transcriptase Products

Biological Activity

Description Tenofovir (GS-1278) hydrate blocks reverse transcriptase and hepatitis B virus infections.

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 305.23
Formula

C9H16N5O5P

CAS No. 206184-49-8
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05140954 Not yet recruiting Drug: co-formulated 25mg TAF/ 200mg FTC HIV Infections University of Washington|Kenya Medical Research Institute|University of Colorado Denver|Gilead Sciences September 2022 Phase 2|Phase 3
NCT05057858 Enrolling by invitation Drug: co-formulated 300 mg TDF/ 200mg FTC HIV Infections University of Washington|University of Colorado Denver|Kenya Medical Research Institute|National Institute of Allergy and Infectious Diseases (NIAID) April 25 2022 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Tenofovir hydrate | Tenofovir hydrate supplier | purchase Tenofovir hydrate | Tenofovir hydrate cost | Tenofovir hydrate manufacturer | order Tenofovir hydrate | Tenofovir hydrate distributor